Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential

被引:13
作者
Monath, Thomas P. [1 ,2 ]
Nichols, Richard [1 ,2 ]
Tussey, Lynda [1 ,2 ]
Scappaticci, Kelly [1 ,2 ]
Pullano, Thaddeus G. [1 ]
Whiteman, Mary D. [3 ]
Vasilakis, Nikos [4 ,5 ]
Rossi, Shannan L. [4 ]
Campos, Rafael Kroon [4 ]
Azar, Sasha R. [4 ]
Spratt, Heidi M. [6 ]
Seaton, Brent L. [7 ]
Archambault, W. Tad [8 ]
Costecalde, Yanina, V [9 ,10 ]
Moore, Evan H. [10 ]
Hawks, Roger J. [10 ]
Fusco, Joan [1 ,2 ]
机构
[1] Publ Hlth Vaccines LLC, Cambridge, MA 02142 USA
[2] Crozet BioPharma Inc, Lexington, MA 02421 USA
[3] BioReliance Corp, Rockville, MD USA
[4] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
[5] Univ Texas Med Branch, Sealy Ctr Vector Borne & Zoonot Dis, Galveston, TX USA
[6] Univ Texas Med Branch, Dept Prevent Med & Populat Hlth, Galveston, TX USA
[7] Q2 Solut, San Juan Capistrano, CA USA
[8] VirtuStat, North Wales, PA USA
[9] AmplifyBio, West Jefferson, OH USA
[10] Battelle Mem Inst, West Jefferson, OH USA
关键词
BACKBONE STANDARDIZED TEMPLATE; YELLOW-FEVER VACCINES; KEY CONSIDERATIONS; NEUROVIRULENCE; ENCEPHALITIS; FLAVIVIRUS; VECTORS; MONKEYS; INCREASES; CANDIDATE;
D O I
10.1371/journal.ppat.1010658
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors.
引用
收藏
页数:25
相关论文
共 9 条
  • [1] Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease
    Mire, Chad E.
    Versteeg, Krista M.
    Cross, Robert W.
    Agans, Krystle N.
    Fenton, Karla A.
    Whitt, Michael A.
    Geisbert, Thomas W.
    VIROLOGY JOURNAL, 2013, 10
  • [2] Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
    Monath, Thomas P.
    Nichols, Richard
    Feldmann, Friederike
    Griffin, Amanda
    Haddock, Elaine
    Callison, Julie
    Meade-White, Kimberly
    Okumura, Atsushi
    Lovaglio, Jamie
    Hanley, Patrick W.
    Clancy, Chad S.
    Shaia, Carl
    Rida, Wasima
    Fusco, Joan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Recombinant Vesicular Stomatitis Virus-Based Vaccines Against Ebola and Marburg Virus Infections
    Geisbert, Thomas W.
    Feldmann, Heinz
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S1075 - S1081
  • [4] Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine
    DeBuysscher, Blair L.
    Scott, Dana
    Thomas, Tina
    Feldmann, Heinz
    Prescott, Joseph
    NPJ VACCINES, 2016, 1
  • [5] Assessment of a novel recombinant vesicular stomatitis virus with triple mutations in its matrix protein as a vaccine for pigs
    Fang, Xinkui
    Qi, Bing
    Ma, Yufang
    Zhou, Xinchu
    Zhang, Shikuan
    Sun, Tao
    VACCINE, 2015, 33 (46) : 6268 - 6276
  • [6] Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease
    Prescott, Joseph
    DeBuysscher, Blair L.
    Feldmann, Friederike
    Gardner, Donald J.
    Haddock, Elaine
    Martellaro, Cynthia
    Scott, Dana
    Feldmann, Heinz
    VACCINE, 2015, 33 (24) : 2823 - 2829
  • [7] Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial
    ElSherif, May S.
    Brown, Catherine
    MacKinnon-Cameron, Donna
    Li, Li
    Racine, Trina
    Alimonti, Judie
    Rudge, Thomas L.
    Sabourin, Carol
    Silvera, Peter
    Hooper, Jay W.
    Kwilas, Steven A.
    Kilgore, Nicole
    Badorrek, Christopher
    Ramsey, W. Jay
    Heppner, D. Gray
    Kemp, Tracy
    Monath, Thomas P.
    Nowak, Teresa
    McNeil, Shelly A.
    Langley, Joanne M.
    Halperin, Scott A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2017, 189 (24) : E819 - E827
  • [8] A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection
    Woolsey, Courtney
    Strampe, Jamie
    Fenton, Karla A.
    Agans, Krystle N.
    Martinez, Jasmine
    Borisevich, Viktoriya
    Dobias, Natalie S.
    Deer, Daniel J.
    Geisbert, Joan B.
    Cross, Robert W.
    Connor, John H.
    Geisbert, Thomas W.
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S712 - S720
  • [9] First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
    Fuchs, Jonathan D.
    Frank, Ian
    Elizaga, Marnie L.
    Allen, Mary
    Frahm, Nicole
    Kochar, Nidhi
    Li, Sue
    Edupuganti, Srilatha
    Kalams, Spyros A.
    Tomaras, Georgia D.
    Sheets, Rebecca
    Pensiero, Michael
    Tremblay, Marc A.
    Higgins, Terry J.
    Latham, Theresa
    Egan, Michael A.
    Clarke, David K.
    Eldridge, John H.
    OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (03):